View Financial HealthBiotoxtech 배당 및 자사주 매입배당 기준 점검 0/6Biotoxtech 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률2.1%자사주 매입 수익률총 주주 수익률2.1%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트공시 • Aug 27Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.공시 • Jul 30Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.모든 업데이트 보기Recent updates공시 • Mar 17Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: sky garden hall, 5806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩44.8b market cap, or US$30.6m).Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩3,190, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 62% over the past three years.New Risk • Nov 16New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩42.6b market cap, or US$29.3m).분석 기사 • Sep 01Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) is definitely...공시 • Aug 27Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.공시 • Mar 15Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South KoreaNew Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩53.7b market cap, or US$37.4m).분석 기사 • Oct 21Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetBiotoxtech Co., Ltd.'s ( KOSDAQ:086040 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...공시 • Jul 30Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.New Risk • Nov 28New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩95.1b market cap, or US$73.4m).New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (65% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩123.1b market cap, or US$95.0m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩7,110, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 3.6% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 31% share price gain to ₩8,990, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Negligible returns to shareholders over past three years.공시 • Aug 25Biotoxtech Co., Ltd. announced that it has received KRW 18 billion in funding from BNK Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd. and other investorsOn August 24, 2021, Biotoxtech Co., Ltd. closed the transaction.공시 • Aug 21Biotoxtech Co., Ltd. announced that it expects to receive KRW 18000 billion in funding from BNK Securities Co., Ltd., Investment ArmBiotoxtech Co., Ltd.분석 기사 • May 06Is Biotoxtech (KOSDAQ:086040) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Mar 28Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)Today we will run through one way of estimating the intrinsic value of Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) by...분석 기사 • Feb 20Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?Some Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) shareholders are probably rather concerned to see the share price fall 32...Is New 90 Day High Low • Feb 18New 90-day low: ₩11,200The company is down 29% from its price of ₩15,700 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period.분석 기사 • Jan 24Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?Most readers would already be aware that Biotoxtech's (KOSDAQ:086040) stock increased significantly by 15% over the...분석 기사 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩16,700, the stock is trading at a trailing P/E ratio of 57.4x, down from the previous P/E ratio of 68.9x. This compares to an average P/E of 62x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 127%.분석 기사 • Nov 30Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 15% share price gain to ₩20,300, the stock is trading at a trailing P/E ratio of 69.7x, up from the previous P/E ratio of 60.4x. This compares to an average P/E of 102x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 150%.Is New 90 Day High Low • Nov 19New 90-day high: ₩16,050The company is up 59% from its price of ₩10,100 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.Is New 90 Day High Low • Sep 25New 90-day high: ₩14,200The company is up 42% from its price of ₩9,970 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 A086040 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: A086040 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Biotoxtech 배당 수익률 vs 시장A086040의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (A086040)n/a시장 하위 25% (KR)1.0%시장 상위 25% (KR)3.8%업계 평균 (Life Sciences)23.5%분석가 예측 (A086040) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 A086040 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 A086040 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 A086040 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: A086040 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YKR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 08:03종가2026/05/21 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biotoxtech Co., Ltd.는 2명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Young Ok KimDAOL Investment & Securities Co., Ltd.Seung-Ho LeeiM Securities
공시 • Aug 27Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
공시 • Jul 30Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
공시 • Mar 17Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026Biotoxtech Co., Ltd., Annual General Meeting, Mar 27, 2026, at 09:01 Tokyo Standard Time. Location: sky garden hall, 5806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Mar 04New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (₩44.8b market cap, or US$30.6m).
Valuation Update With 7 Day Price Move • Feb 20Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₩3,190, the stock trades at a trailing P/E ratio of 57x. Average trailing P/E is 17x in the Life Sciences industry in South Korea. Total loss to shareholders of 62% over the past three years.
New Risk • Nov 16New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 7.6% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (7.6% operating cash flow to total debt). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (₩42.6b market cap, or US$29.3m).
분석 기사 • Sep 01Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetYou may think that with a price-to-sales (or "P/S") ratio of 1.1x Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) is definitely...
공시 • Aug 27Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till February 26, 2026. As of August 26, 2025, the company had 237,458 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
공시 • Mar 15Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025Biotoxtech Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:00 Tokyo Standard Time. Location: conference room, 806, jungbu-ro, cheongwon-gu, chungcheongbuk-do, cheongju South Korea
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (₩53.7b market cap, or US$37.4m).
분석 기사 • Oct 21Improved Revenues Required Before Biotoxtech Co., Ltd. (KOSDAQ:086040) Shares Find Their FeetBiotoxtech Co., Ltd.'s ( KOSDAQ:086040 ) price-to-sales (or "P/S") ratio of 2.2x might make it look like a buy right...
공시 • Jul 30Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces an Equity Buyback for KRW 1,000 million worth of its shares.Biotoxtech Co., Ltd. (KOSDAQ:A086040) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 million worth of its shares under the contract with Eugene Investment & Securities. The purpose of the program is to stabilize the stock price, to enhance the shareholders’ value. The program will be valid till January 29, 2025. As of July 29, 2024, the company had 30,735 shares in treasury under the dividend capacity and 0 shares in treasury under other capacities.
New Risk • Nov 28New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 0.2% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩95.1b market cap, or US$73.4m).
New Risk • Jun 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (65% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (0.5% net profit margin). Shareholders have been diluted in the past year (8.8% increase in shares outstanding). Market cap is less than US$100m (₩123.1b market cap, or US$95.0m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jun 22Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ₩7,110, the stock trades at a trailing P/E ratio of 15.6x. Average trailing P/E is 27x in the Life Sciences industry in South Korea. Total returns to shareholders of 3.6% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Feb 18Investor sentiment improved over the past weekAfter last week's 31% share price gain to ₩8,990, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 25x in the Life Sciences industry in South Korea. Negligible returns to shareholders over past three years.
공시 • Aug 25Biotoxtech Co., Ltd. announced that it has received KRW 18 billion in funding from BNK Securities Co., Ltd., Investment Arm, Mirae Asset Securities Co., Ltd. and other investorsOn August 24, 2021, Biotoxtech Co., Ltd. closed the transaction.
공시 • Aug 21Biotoxtech Co., Ltd. announced that it expects to receive KRW 18000 billion in funding from BNK Securities Co., Ltd., Investment ArmBiotoxtech Co., Ltd.
분석 기사 • May 06Is Biotoxtech (KOSDAQ:086040) A Risky Investment?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Mar 28Estimating The Fair Value Of Biotoxtech Co., Ltd. (KOSDAQ:086040)Today we will run through one way of estimating the intrinsic value of Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) by...
분석 기사 • Feb 20Did Biotoxtech's (KOSDAQ:086040) Share Price Deserve to Gain 91%?Some Biotoxtech Co., Ltd. ( KOSDAQ:086040 ) shareholders are probably rather concerned to see the share price fall 32...
Is New 90 Day High Low • Feb 18New 90-day low: ₩11,200The company is down 29% from its price of ₩15,700 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 2.0% over the same period.
분석 기사 • Jan 24Are Robust Financials Driving The Recent Rally In Biotoxtech Co., Ltd.'s (KOSDAQ:086040) Stock?Most readers would already be aware that Biotoxtech's (KOSDAQ:086040) stock increased significantly by 15% over the...
분석 기사 • Dec 27We're Not So Sure You Should Rely on Biotoxtech's (KOSDAQ:086040) Statutory EarningsAs a general rule, we think profitable companies are less risky than companies that lose money. Having said that...
Valuation Update With 7 Day Price Move • Dec 12Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to ₩16,700, the stock is trading at a trailing P/E ratio of 57.4x, down from the previous P/E ratio of 68.9x. This compares to an average P/E of 62x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 127%.
분석 기사 • Nov 30Is Biotoxtech (KOSDAQ:086040) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Valuation Update With 7 Day Price Move • Nov 30Market bids up stock over the past weekAfter last week's 15% share price gain to ₩20,300, the stock is trading at a trailing P/E ratio of 69.7x, up from the previous P/E ratio of 60.4x. This compares to an average P/E of 102x in the Life Sciences industry in South Korea. Total returns to shareholders over the past three years are 150%.
Is New 90 Day High Low • Nov 19New 90-day high: ₩16,050The company is up 59% from its price of ₩10,100 on 21 August 2020. The South Korean market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Sep 25New 90-day high: ₩14,200The company is up 42% from its price of ₩9,970 on 26 June 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Life Sciences industry, which is down 12% over the same period.